Analysts expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to post sales of $4.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Adamis Pharmaceuticals’ earnings, with estimates ranging from $3.60 million to $4.50 million. The company is scheduled to report its next quarterly earnings report on Thursday, March 29th.
According to Zacks, analysts expect that Adamis Pharmaceuticals will report full-year sales of $4.05 million for the current year, with estimates ranging from $13.80 million to $14.73 million. For the next year, analysts expect that the business will post sales of $20.05 million per share, with estimates ranging from $18.40 million to $21.69 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Adamis Pharmaceuticals.
A number of equities research analysts have recently weighed in on ADMP shares. B. Riley reiterated a “buy” rating and issued a $9.50 price objective on shares of Adamis Pharmaceuticals in a research report on Wednesday, October 4th. ValuEngine lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Zacks Investment Research lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Finally, Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.33.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADMP. First Allied Advisory Services Inc. bought a new stake in shares of Adamis Pharmaceuticals during the second quarter valued at approximately $114,000. Stonebridge Capital Advisors LLC boosted its position in shares of Adamis Pharmaceuticals by 22.2% during the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Adamis Pharmaceuticals by 131.0% during the third quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 15,577 shares in the last quarter. Wells Fargo & Company MN bought a new stake in shares of Adamis Pharmaceuticals during the second quarter valued at approximately $169,000. Finally, Virtu KCG Holdings LLC boosted its position in shares of Adamis Pharmaceuticals by 103.2% during the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock valued at $200,000 after purchasing an additional 19,538 shares in the last quarter. Institutional investors own 16.61% of the company’s stock.
Shares of Adamis Pharmaceuticals (NASDAQ ADMP) traded down $0.03 during mid-day trading on Friday, hitting $4.43. The stock had a trading volume of 364,891 shares, compared to its average volume of 523,601. Adamis Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $6.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.79 and a current ratio of 3.93.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/13/analysts-anticipate-adamis-pharmaceuticals-corp-admp-will-post-quarterly-sales-of-4-05-million.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.